ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "clinical trial"

  • Abstract Number: 2233 • ACR Convergence 2023

    Neutrophil Levels Associate with Early Improvement in Spinal Pain and Week 24 Multi-Domain Disease Control During Guselkumab Treatment in Active Psoriatic Arthritis: Post Hoc Pooled Analyses of Two Phase 3 Randomized Controlled Trials

    Thomas Macleod1, Xenofon Baraliakos2, Emmanouil Rampakakis3, Warner Chen4, Antonius Pieter J Van Den Heuvel4, Loqmane Seridi4, May Shawi5, Frederic Lavie6, Joseph F. Merola7, Proton Rahman8 and Dennis McGonagle9, 1University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, 2Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, 3McGill University, Department of Pediatrics / JSS Medical Research, Scientific Affairs, Montreal, QC, Canada, 4Translational Sciences, Janssen Research & Development, LLC, Spring House, PA, 5Immunology, Janssen Research & Development, LLC, Titusville, NJ, 6The Janssen Pharmaceutical Companies of Johnson & Johnson, Paris, France, 7Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 8Craig Dobbin Research Institute, Memorial University, St. John's, NL, Canada, 9Leeds Biomedical Research Centre, University of Leeds, Leeds, United Kingdom

    Background/Purpose: Neutrophils have potential pathogenic roles in chronic inflammatory diseases (e.g., neutrophilic cutaneous microabscesses in psoriasis, and neutrophils in the synovial fluid/tissue in PsA and…
  • Abstract Number: 2345 • ACR Convergence 2023

    Paired Kidney Biopsies from the AURORA 2 Study of Voclosporin in Active Lupus Nephritis

    Samir Parikh1, Salem Almaani2, Arnon Arazi3, Huijuan Song1, Pearlly Yan1, Estela Puchulu-Campanella1, Clint Abner4, Ernie Yap4, Krista Piper4, Robert B. Huizinga5 and Henry Leher4, 1Ohio State University, Columbus, OH, 2Ohio State University Medical Center, Columbus, OH, 3Broad Institute of MIT and Harvard, Melrose, MA, 4Aurinia Pharmaceuticals Inc., Edmonton, AB, Canada, 5Reformation Consulting Services, North Saanich, BC, Canada

    Background/Purpose: Voclosporin is approved for the treatment of adults with active lupus nephritis. Addition of voclosporin to mycophenolate mofetil (MMF) and low-dose glucocorticoids in the…
  • Abstract Number: 0372 • ACR Convergence 2023

    Efficacy and Safety of Secukinumab in Juvenile Idiopathic Arthritis: Interim Results from the Extension of the JUNIPERA Trial

    Hermine Brunner1, Ivan Foeldvari2, Ekaterina Alexeeva3, Nuray Aktay Ayaz4, Grant Schulert5, Seza Ozen6, Artem Popov7, Athimalaipet V Ramanan8, Christiaan Scott9, Betul Sozeri10, Elena Zholobova11, Sudhanshu Chakraborty12, Xuan Zhu13, Ruvie Martin13, Sarah Whelan14, Sharonjeet Kaur15, Luminita Pricop13, Daniel J Lovell16, Alberto Martini17 and Nicolino Ruperto18, 1Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH, 2Hamburger Zentrum fuer Kinder und Jugendrheumatologie, Rheumatology, Hamburg, Germany, 3National Scientific and Practical Center of Children's Health, Rheumatology, Moscow, Russia, 4Department of Pediatric Rheumatology, Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey, 5Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 6Hacettepe University Medical Faculty, Ankara, Turkey, 7Ural State Medical University Ekaterinburg, Sverdlovsk, Russia, 8Bristol Royal Hospital for Children & Translational Health Sciences, University of Bristol, Bristol, United Kingdom, 9Department of Paediatric Rheumatology, Red Cross War Memorial Children’s Hospital, University of Cape Town, Cape Town, South Africa, 10Division of Pediatric Rheumatology, University of Health Sciences, Ümraniye Training and Research Hospital, Istanbul, Turkey, 11First Moscow State Medical University, n.a. I.M.Sechenov, Moscow, Russia, 12IQVIA, Durrham, NC, 13Novartis Pharmaceuticals Corporation, East Hanover, NJ, 14Novartis Ireland Ltd, Dublin, Ireland, 15Novartis Pharma AG, Basel, Switzerland, 16UC Department of Pediatrics, Cincinnati Children's Hospital, University of Cincinnati, Cincinnati, OH, 17Università di Genova, Genova, Italy, 18IRCCS Istituto Giannina Gaslini, UOSID Centro Trial, Genova, Italy

    Background/Purpose: Secukinumab has demonstrated efficacy and safety in patients with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) categories of juvenile idiopathic arthritis (JIA) for…
  • Abstract Number: 0600 • ACR Convergence 2023

    Identification of Subsets of SLE Patients Responsive to Baricitinib by Transcriptomic Analysis at Baseline

    Prathyusha Bachali1, Amrie Grammer2 and Peter Lipsky2, 1AMPEL BioSolutions, Redmond, WA, 2AMPEL BioSolutions, Charlottesville, VA

    Background/Purpose: Baricitinib is an inhibitor of Jak1 approved for treatment of rheumatoid arthritis, atopic dermatitis, alopecia areata and Covid-19. A phase 2 trial showed success…
  • Abstract Number: 1104 • ACR Convergence 2023

    Dotinurad, a Potent and Selective Uricosuric Agent, Exhibited Promising Pharmacokinetics and Pharmacodynamic Profiles to Significantly Reduce Serum Urate Levels Following Once Daily Dosing in Healthy U.S. Subjects in a Phase 1 Clinical Trial

    Scott Baumgartner, Raymond Zheng, Mark Harnett and Jay Kranzler, Urica Therapeutics Inc., New York, NY

    Background/Purpose: Dotinurad is a potent and selective URAT1 inhibitor that has been approved as a once-daily drug for the treatment of hyperuricemia with or without…
  • Abstract Number: 1379 • ACR Convergence 2023

    Population Pharmacokinetic/Pharmacodynamic Modeling of Dazodalibep, a CD40L Antagonist, in Healthy Volunteers and Patients with Rheumatoid Arthritis and Sjogren’s Syndrome

    Kenneth Der1, Ryan Crass2, Brendan Smith3, Wonkyung Byon4, Yan Xin5 and Jiayin Huang6, 1Horizon Therapeutics, Danville, CA, 2Apellis Pharmaceuticals, Michigan, 3A2-Ai, Michigan, 4Amador Bioscience, Michigan, 5Horizon Therapeutics, South San Francisco, CA, 6Horizon Therapeutics, Chicago, IL

    Background/Purpose: Sjögren's (SjS) is a chronic, systemic autoimmune disease caused by aberrant activation and infiltration of lymphocytes. Dazodalibep (DAZ), a novel non-antibody biologic antagonist of…
  • Abstract Number: 1505 • ACR Convergence 2023

    Long-term Safety and Efficacy of Voclosporin in Black Patients with Lupus Nephritis: Results from the AURORA 1 and AURORA 2 Studies

    Gabriel Contreras1, Matt Baker2, Lucy Hodge2 and Ernie Yap2, 1University of Miami Health System, Miami, FL, 2Aurinia Pharmaceuticals Inc., Edmonton, AB, Canada

    Background/Purpose: Black patients with lupus nephritis (LN) are reported to have more severe disease, are often refractory to treatment, and have worse long-term outcomes. Voclosporin…
  • Abstract Number: 1972 • ACR Convergence 2023

    Evaluation of Myositis Autoantibodies as Predictors of Response to IVIG: Post-hoc Analysis of a Large Randomized, Double-Blind, Placebo-Controlled Phase III Trial

    Christina Charles-Schoeman1, Joachim Schessl2, Rohit Aggarwal3 and and the ProDERM investigators4, 1UCLA Medical Center, Santa Monica, CA, 2Friedrich-Baur-Institute, Ludwig-Maximilians University of Munich, Munich, Germany, 3University of Pittsburgh, Pittsburgh, PA, 4Institutions in Europe and North America, Vienna, Austria

    Background/Purpose: Dermatomyositis (DM) is an immune-mediated inflammatory myopathy (IIM). Two subsets ofautoantibodies have been identified in patients with IIM: Myositis-specific antibodies (MSA) and myositis-associated antibodies…
  • Abstract Number: 2239 • ACR Convergence 2023

    Achievement of Disease Control in PsA Patients Treated with Upadacitinib at Week 152: Post Hoc Analysis of the Long-term Extensions of Two Phase 3 Trials

    Arthur Kavanaugh1, Kristi Mizelle2, Oliver FitzGerald3, Enrique Soriano4, Peter Nash5, Sandra Ciecinski6, Limei Zhou6, Arathi Setty6 and Laure Gossec7, 1Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, 2Tidewater Physicians Multispecialty Group, Newport News, VA, 3Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland, 4Rheumatology Section, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 5School of Medicine, Griffith University, Brisbane, Australia, 6AbbVie, Inc., North Chicago, IL, 7Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France

    Background/Purpose: A main goal of therapy for patients (pts) with PsA is to achieve and maintain the lowest possible level of disease activity across domains.1…
  • Abstract Number: 2486 • ACR Convergence 2023

    Should SLE Patients Entering Clinical Trials Be Required to Have at Least One BILAG a And/or Two BILAG B Scores?

    Ewa Olech1 and Joan Merrill2, 1IQVIA, Rheumatology Consultants, PLLC, Las Vegas, NV, 2Oklahoma Medical Research Foundation, Oklahoma City, OK

    Background/Purpose: High placebo response rates have challenged interpretation of clinical trial results in SLE and may have contributed to failure of some effective treatments. One…
  • Abstract Number: 0429 • ACR Convergence 2023

    Direct and Indirect Effects of Upadacitinib or Adalimumab on Pain in Rheumatoid Arthritis: Results from a Randomized Phase 3 Study

    Peter C. Taylor1, David Walsh2, Tsutomu Takeuchi3, Bruno Fautrel4, Janet Pope5, Andrew Garrison6, Yanna Song6, Sara K. Penn6, Ralph Lippe7, Diane Caballero8 and Arthur Kavanaugh9, 1Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 2University of Nottingham, Nottingham, United Kingdom, 3Keio University School of Medicine and Saitama Medical University, Tokyo, Japan, 4Sorbonne Université APHP, Paris, France, 5University of Western Ontario, London, ON, Canada, 6AbbVie, Inc., North Chicago, IL, 7AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, 8AbbVie, Inc., Chicago, IL, 9University of California San Diego, School of Medicine, Riverside, CA

    Background/Purpose: Rapid and sustained pain control is an important goal for patients (pts) with rheumatoid arthritis (RA). Control of inflammation in RA does not always…
  • Abstract Number: 0625 • ACR Convergence 2023

    Use of Heated Gloves for Raynaud’s Phenomenon in Systemic Sclerosis

    Kimti Kumar1, Nor Hashimah Abu Mansor Matardiah2, Kim Griggs3, Aline Kunnel4, Jennifer Walker5 and Susanna Proudman6, 1SA Health and University of Adelaide, Millswood, Australia, 2Tuanku Fauziah Hospital, Kangar, Malaysia, 3Royal Adelaide Hospital, Adelaide, Australia, 4South Australian Health and Medical Research Institute, Adelaide, Australia, 5Flinders Medical Centre and Royal Adelaide Hospital, Bedford Park, Australia, 6Royal Adelaide Hospital and University of Adelaide, Adelaide, Australia

    Background/Purpose: RP and its ischaemic complications are a major cause of morbidity in SSc. Non-pharmacological measures to minimise cold exposure can play a vital role…
  • Abstract Number: 1110 • ACR Convergence 2023

    Pharmacokinetics and Pharmacodynamics of AR882 Following 12-Week Treatment in Patients with Gout

    Roy Fleischmann1, James Cheng-Chung Wei2, Zancong Shen3, sarah Morris4, Elizabeth Polvent5, Andrea Clouser-Roche4, Vijay Hingorani6, Rongzi Yan7, Shunqi Yan8, Robert Keenan9 and Li-Tain Yeh10, 1Division of Rheumatology, University of Texas Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX, 2Chung Shan Medical University Hospital, Department of Rheumatology, Taichung, Taiwan, 3Arthrosi Therapeutics, San Diego, CA, 4Arthrosi Therapeutics Inc, San Diego, CA, 5Arthrosi Therapeutics, Inc., Roseville, CA, 6Vanguard Healthsciences, Inc., San Diego, CA, 7Arthrosi Therapeutics, Inc, Irvine, CA, 8Arthrosi Therapeutics, Inc., Laguna Hills, CA, 9Arthrosi Therapeutics, Chapel Hill, NC, 10Arthrosi Therapeutics, Inc., Irvine, CA

    Background/Purpose: In early phase studies AR882 exhibited good dose proportionality, long half-life and dose-dependent serum urate (sUA) lowering effect in a broad range of doses…
  • Abstract Number: 1397 • ACR Convergence 2023

    Sustainability of Clinical Response at Week 52 to Upadacitinib Among Patients with Axial SpA: Data from the SELECT-AXIS 1 and SELECT-AXIS 2 Trials

    Victoria Navarro-Compán1, Lianne Gensler2, Martin Rudwaleit3, Fabiana Ganz4, Shirley Chen4, Jayne Stigler4, Anna Schmagel4 and Xenofon Baraliakos5, 1Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, 2University of California San Francisco, Department of Medicine, Division of Rheumatology, San Francisco, CA, 3University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, 4AbbVie, Inc., North Chicago, IL, 5Rheumazentrum Ruhrgebiet Herne, Ruhr University Bochum, Bochum, Germany

    Background/Purpose: Upadacitinib 15 mg (UPA), an oral Janus kinase inhibitor, has shown efficacy and tolerability through 14 weeks in patients (pts) with active radiographic axial…
  • Abstract Number: 1511 • ACR Convergence 2023

    B-Cell Recovery in a Randomized Controlled Trial of B-Cell Depletion with Obinutuzumab for the Treatment of Proliferative Lupus Nephritis

    Ed Vital1, Dario Roccatello2, David Black3, Rhian Jacob-Moffatt4, Cary M. Looney5, Elsa Martins5, Huiyan (Ashley) Mao3, Thomas Schindler6, Himanshi Seghal5, Jay Garg7, Jorge Ross Terres7 and Richard Furie8, 1University of Leeds, Leeds, United Kingdom, 2University of Torino, Torino, Italy, 3Hoffmann-La Roche Ltd, Mississauga, ON, Canada, 4F. Hoffmann-La Roche Ltd, Welwyn Garden City, United Kingdom, 5F. Hoffmann-La Roche Ltd, Basel, Switzerland, 6F. Hoffmann-La Roche Ltd, Basle, Switzerland, 7Genentech, Inc., South San Francisco, CA, 8Northwell Health, Manhasset, NY

    Background/Purpose: Patients with LN who received obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, with standard-of-care (MMF) immunosuppression (Phase II NOBILITY; NCT02550652; PMID 34615636) showed…
  • « Previous Page
  • 1
  • …
  • 14
  • 15
  • 16
  • 17
  • 18
  • …
  • 44
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology